These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33454519)

  • 21. Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study.
    Tian J; Wang H; Lu C; Liu L; Zhang X; Xie Y; Li R; Lv X; Fu D; Zhang L; Fang X; Wang X; Hu J; Liu X; Huang X; Zhao Q; Luo N; Tang H; Zhong Z; He Y; Li L
    Lung Cancer; 2023 Jul; 181():107255. PubMed ID: 37244039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
    Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
    Abdel-Wahab R; Yap TA; Madison R; Pant S; Cooke M; Wang K; Zhao H; Bekaii-Saab T; Karatas E; Kwong LN; Meric-Bernstam F; Borad M; Javle M
    Sci Rep; 2020 Dec; 10(1):22087. PubMed ID: 33328484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
    Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
    J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
    Wu Q; Wang W; Zhou P; Fu Y; Zhang Y; Shao YW; Jiang L
    Pathol Res Pract; 2020 Aug; 216(8):153043. PubMed ID: 32703503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
    Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
    J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
    Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
    Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
    J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
    Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
    Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive molecular profiling of pulmonary pleomorphic carcinoma.
    Nagano M; Kohsaka S; Hayashi T; Ueno T; Kojima S; Shinozaki-Ushiku A; Morita S; Tsuda M; Tanaka S; Shinohara T; Omori Y; Sugaya F; Kato H; Narita Y; Nakajima J; Suzuki K; Takamochi K; Mano H
    NPJ Precis Oncol; 2021 Jun; 5(1):57. PubMed ID: 34158601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
    Dudnik E; Peled N; Nechushtan H; Wollner M; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadari N; Urban D; Mishaeli M; Zer A; Allen AM; Rabinovich NM; Rotem O; Kuznetsov T; Shochat T; Roisman LC; Bar J;
    J Thorac Oncol; 2018 Aug; 13(8):1128-1137. PubMed ID: 29723688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas.
    Qin J; Chen B; Li C; Yan J; Lu H
    Cancer Genet; 2021 Jan; 250-251():12-19. PubMed ID: 33217678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
    Jiao Y; Liu M; Luo N; Guo H; Li J
    Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
    Dudnik E; Bshara E; Grubstein A; Fridel L; Shochat T; Roisman LC; Ilouze M; Rozenblum AB; Geva S; Zer A; Rotem O; Allen AM; Peled N
    Lung Cancer; 2018 Oct; 124():117-124. PubMed ID: 30268448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I
    Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.